Other

Btg International Limited

Pharmacia Ab

King's College London

Kings College

Deutsches Wollforschuncsinstitut an Der Rwth Aachen

Deutsches Wollforschungsinstitut

Peter Henri Sonksen

Dietrich Brandenburg

Achim Schuttler

Fariba Shojaee-Moradi

Richard Henry Jones

Heike Eckey

David B Dunger

Henry R Jones

Martin O Savage

Miroslav Wurzburger

Erik Sundermann

The invention provides an analogue of a pharmaceutical active whose molecular weight is less than 25,000 Daltons, the analogue comprising a pharmaceutical active whose molecular weight is less than 25,000 Daltons covalently linked to a pendant molecular group wherein as a result of the administration of the composition to the human or animal body an active complex having a molecular weight of 25,000 Daltons or greater is present in the human or animal circulatory system. The analogue is hepatoselective when administered to the circulatory system. Preferably the analogue is an insulin analogue comprising an insulin or functional equivalent thereof covalently linked to the pendant molecular group wherein the active complex is an insulin complex. Such an insulin analogue may be used in a method of insulin replacement therapy.

Hepatoselective pharmaceutical actives

Pharmaceutical active conjugates

Use of IGF-1

The invention relates to the use of human growth hormone, or any functional analogue therof, for the manufacture of a medicament for the treatment or prophylaxis of hypoglycemic unawareness in diabetes mellitus. Preferably the human growth hormone, or any functional analogue thereof, is administered repeatedly, which could be daily. The daily dose is between 1-10 IU and could be given at a dose of 4 IU daily during one week. The invention also relates to a method for treatment and prophylaxis of hypoglycemic unawareness by administration of human growth hormone, or any funtional analogue thereof.

Use of human growth hormone

Growing community of inventors

London, United Kingdom

Peter Henri Sonksen